natgillin/translations-raw huggingface dataset:
Each chewable tablet contains:
Üks närimistablett sisaldab:
Each child-resistant sachet is made of a paper/polyester/aluminium/polyacrylonitrile multilaminated material.
Iga lastekindel kotike on valmistatud multilamineeritud materjalist (paber/polüester/alumiinium/polüakrüülonitriil).
Each clear, plastic bottle contains 100 ml of a clear, colourless solution.
Iga läbipaistvast plastikust pudel sisaldab 100 ml selget, värvitut lahust.
Each clear, plastic or glass vial contains 5 ml of a clear, colourless solution.
Iga läbipaistvast plastikust või klaasist viaal sisaldab 5 ml selget, värvitut lahust.
Each coated tablet contains 10 mg olanzapine
Iga kaetud tablett sisaldab 10 mg olansapiini
Each coated tablet contains 15 mg olanzapine
Iga kaetud tablett sisaldab 15 mg olansapiini
Each coated tablet contains 170 mg lactose (as monohydrate).
Üks õhukese polümeerikattega tablett sisaldab 170 mg laktoosi (monohüdraadina).
Each coated tablet contains 2.5 mg olanzapine
Iga kaetud tablett sisaldab 2,5 mg olansapiini
Each coated tablet contains 2.5 mg olanzapine
Iga kaetud tablett sisaldab 2,5 mg olansapiini.
Each coated tablet contains 20 mg olanzapine
Iga kaetud tablett sisaldab 20 mg olansapiini.
Each coated tablet contains 29.74 mg of lactose.
Üks õhukese polümeerikattega tablett sisaldab 29,74 mg laktoosi.
Each coated tablet contains 5 mg olanzapine
Iga kaetud tablett sisaldab 5 mg olansapiini
Each coated tablet contains 5 mg olanzapine
Iga kaetud tablett sisaldab 5 mg olansapiini.
Each coated tablet contains 7.5 mg olanzapine
Iga kaetud tablett sisaldab 7,5 mg olansapiini
Each coated tablet contains 7.5 mg olanzapine
Iga kaetud tablett sisaldab 7,5 mg olansapiini.
Each container contains 3.8 cm2 of autologous human corneal epithelium attached on a fibrin support and covered with transport medium.
Iga konteiner sisaldab 3,8 cm2 autoloogilist inimese sarvkesta epiteeli, mis on kinnitatud fibriinalusele transportsöötmes.
Each container contains 3.8 cm2 of autologous human corneal epithelium attached to a fibrin support and immersed in transport medium.
Üks konteiner sisaldab 3,8 cm2 autoloogilist inimese sarvkesta epiteeli, mis on kinnitatud fibriinalusele transportsöötmes.
Each container delivers a minimum of 20 doses (6.5 ml) or 12 doses (5.0 ml).
Ühes mahutis on vähemalt 20 annust (6,5 ml) või 12 annust (5,0 ml).
Each container includes 10ml equivalent to 1000 units insulin lispro.
Iga viaal sisaldab 10 ml, vastavalt 1000 ühikut lispro-insuliini.
Each container includes 10ml equivalent to 1000U insulin lispro.
Iga mahuti sisaldab 10 ml, mis võrdub 1000 TÜ lispro-insuliiniga.
Each container includes 10ml equivalent to 1000U insulin lispro.
Iga viaal sisaldab 10 ml, vastavalt 1000 TÜ lispro-insuliini.
Each container includes 3ml equivalent to 300 units insulin lispro.
Iga mahuti sisaldab 3 ml, mis võrdub 300 ühiku lispro- insuliiniga.
Each container includes 3ml equivalent to 300 units insulin lispro.
Iga mahuti sisaldab 3 ml, vastavalt 300 ühikut lispro-insuliini.
Each container includes 3ml equivalent to 300U insulin lispro.
Iga mahuti sisaldab 3 ml, mis võrdub 300 TÜ lispro-insuliiniga.
Each container includes 3ml equivalent to 300U insulin lispro.
Iga mahuti sisaldab 3 ml, vastavalt 300 TÜ lispro-insuliini.
Each container is closed with a 20 mm bromobutyl rubber stopper and a central tear-off aluminium-plastic cap.
Iga pudel on suletud bromobutüülkummist korgi ja keskelt eemaldatava alumiinium-plastikust kattega.
Each containing 250 mg of cream.
Iga kotike sisaldab 250 mg kreemi.
Each Corbilta 100 mg/25 mg/200 mg tablet contains 100 mg of levodopa, 25 mg of carbidopa and 200 mg of entacapone.
Iga Corbilta 100 mg/25 mg/200 mg tablett sisaldab 100 mg levodopat, 25 mg karbidopat ja 200 mg entakapooni.
Each Corbilta 125 mg/31.25 mg/200 mg tablet contains 125 mg of levodopa, 31.25 mg of carbidopa and 200 mg of entacapone.
Iga Corbilta 125 mg/31,25 mg/200 mg tablett sisaldab 125 mg levodopat, 31,25 mg karbidopat ja 200 mg entakapooni.
Each Corbilta 150 mg/37.5 mg/200 mg tablet contains 150 mg of levodopa, 37.5 mg of carbidopa and 200 mg of entacapone.
Iga Corbilta 150 mg/37,5 mg/200 mg tablett sisaldab 150 mg levodopat, 37,5 mg karbidopat ja 200 mg entakapooni.
Each Corbilta 175 mg/43.75 mg/200 mg tablet contains 175 mg of levodopa, 43.75 mg of carbidopa and 200 mg of entacapone.
Iga Corbilta 175 mg/43,75 mg/200 mg tablett sisaldab 175 mg levodopat, 43,75 mg karbidopat ja 200 mg entakapooni.
Each Corbilta 200 mg/50 mg/200 mg tablet contains 200 mg of levodopa, 50 mg of carbidopa and 200 mg of entacapone.
Iga Corbilta 200 mg/50 mg/200 mg tablett sisaldab 200 mg levodopat, 50 mg karbidopat ja 200 mg entakapooni.
Each Corbilta 50 mg/12.5 mg/200 mg tablet contains 50 mg of levodopa, 12.5 mg of carbidopa and 200 mg of entacapone.
Iga Corbilta 50 mg/12,5 mg/200 mg tablett sisaldab 50 mg levodopat, 12,5 mg karbidopat ja 200 mg entakapooni.
Each Corbilta 75 mg/18.75 mg/200 mg tablet contains 75 mg of levodopa, 18.75 mg of carbidopa and 200 mg of entacapone.
Iga Corbilta 75 mg/18,75 mg/200 mg tablett sisaldab 75 mg levodopat, 18,75 mg karbidopat ja 200 mg entakapooni.
Each cycle of treatment is separated by a 14 day (2 week) treatment-free interval.
Järjestikuste ravikuuride vahele jääb ravivaba periood kestusega 14 päeva (2 nädalat).
Each cycle of treatment is separated by a 2 week treatment-free interval.
Iga ravitsükli vahele jääb 2-nädalane ravivaba intervall.
Each daily dose of 160 mg contains 1.68 mg of lecithin (derived from soya).
Ööpäevane annus (160 mg) sisaldab 1,68 mg letsitiini (saadud sojast).
Each daily dose of 160 mg contains 2.427 mmol (or 55.8 mg) of sodium.
Ööpäevane annus (160 mg) sisaldab 2,427 mmol (55,8 mg) naatriumi.
Each day, the vial should be taken from the numbered spot that matches the calendar day to make sure a daily dose is not missed.
Iga päev tuleb viaal võtta kalendripäevale vastavast nummerdatud kohast, see aitab vältida igapäevase annuse unustamist.
Each delivered (inhaled) dose contains 320 micrograms of budesonide and 9 micrograms of formoterol fumarate dihydrate.
Üks annustatav (inhaleeritav) kogus sisaldab 320 mikrogrammi budesoniidi ja 9 mikrogrammi formoteroolfumaraatdihüdraati.
Each delivered dose (the dose from the mouthpiece) contains 45 micrograms of salmeterol (as salmeterol xinafoate) and 465 micrograms of fluticasone propionate.
Üks inhaleeritav annus (huulikust saadav annus) sisaldab 45 mikrogrammi salmeterooli (salmeteroolksinafoaadina) ja 465 mikrogrammi flutikasoonpropionaati.
Each delivered dose (the dose leaving the mouthpiece) contains 375 µg aclidinium bromide equivalent to 322 µg of aclidinium.
Üks manustatud annus (huuliku kaudu väljuv annus) sisaldab 375 µg aklidiinbromiidi, mis on võrdne 322 µg aklidiiniga.
Each delivered dose (the dose leaving the mouthpiece) contains 396 micrograms of aclidinium bromide (equivalent to 340 micrograms of aclidinium) and 11.8 micrograms of formoterol fumarate dihydrate.
Üks manustatud annus (huuliku kaudu väljuv annus) sisaldab 396 mikrogrammi aklidiiniumbromiidi (võrdub 340 mikrogrammi aklidiiniga) ja 11,8 mikrogrammi formoteroolfumaraatdihüdraati.
Each delivered dose (the dose that leaves the mouthpiece of the inhaler) contains 110 µg of indacaterol maleate equivalent to 85 µg of indacaterol and 54 µg of glycopyrronium bromide equivalent to 43 µg of glycopyrronium.
Üks inhaleeritav annus (annus, mis väljutatakse inhalaatori huulikust) sisaldab 110 µg indakateroolmaleaati, mis vastab 85 µg indakateroolile ja 54 µg glükopürrooniumbromiidi, mis vastab 43 µg glükopürrooniumile.
Each delivered dose (the dose that leaves the mouthpiece of the Spiromax) contains 160 micrograms of budesonide and 4.5 micrograms of formoterol fumarate dihydrate.
Üks manustatav annus (Spiromax’i huulikult väljuv annus) sisaldab 160 mikrogrammi budesoniidi ja 4,5 mikrogrammi formoteroolfumaraatdihüdraati.
Each delivered dose (the dose that leaves the mouthpiece of the Spiromax) contains 320 micrograms of budesonide and 9 micrograms of formoterol fumarate dihydrate.
Üks manustatav annus (Spiromax’i huulikult väljuv annus) sisaldab 320 mikrogrammi budesoniidi ja 9 mikrogrammi formoteroolfumaraatdihüdraati.
Each delivered dose contains 375 micrograms aclidinium bromide equivalent to 322 micrograms of aclidinium.
Iga manustatud annus sisaldab 375 mikrogrammi aklidiinbromiidi, mis on võrdne 322 mikrogrammi aklidiiniga.
Each delivered dose contains 375 micrograms aclidinium bromide equivalent to 322 micrograms of aclidinium.
Üks manustatud annus sisaldab 375 mikrogrammi aklidiinbromiidi, mis on võrdne 322 mikrogrammi aklidiiniga.
Each delivered dose contains 396 micrograms aclidinium bromide (equivalent to 340 micrograms of aclidinium) and 11.8 micrograms of formoterol fumarate dihydrate.
Üks manustatud annus sisaldab 396 mikrogrammi aklidiiniumbromiidi (võrdub 340 mikrogrammi aklidiiniga) ja 11,8 mikrogrammi formoteroolfumaraatdihüdraati.
Each delivered dose contains 396 micrograms aclidinium bromide equivalent to 340 micrograms of aclidinium and
Iga manustatud annus sisaldab 396 mikrogrammi aklidiiniumbromiidi, mis vastab 340 mikrogrammile aklidiinile, ja 11,8 mikrogrammi formoteroolfumaraatdihüdraati.
Each delivered dose contains 396 micrograms aclidinium bromide equivalent to 340 micrograms of aclidinium and 11.8 micrograms of formoterol fumarate dihydrate.
Iga manustatud annus sisaldab 396 mikrogrammi aklidiiniumbromiidi, mis vastab 340 mikrogrammile aklidiinile, ja 11,8 mikrogrammi formoteroolfumaraatdihüdraati.
Each dish contains 1 implantation matrix, held in place by a green polycarbonate x-ring and closed with a green polycarbonate cover for shipment.
Üks anum sisaldab ühte implantatsioonimaatriksit, mida hoiab paigal roheline polükarbonaadist X- rõngas, ning on suletud rohelise polükarbonaatkaanega.
Each dispersible tablet contains 1.96 mg lactose.
Iga dispergeeruv tablett sisaldab 1,96 mg laktoosi.
Each dispersible tablet contains 125 mg deferasirox.
Üks dispergeeruv tablett sisaldab 125 mg deferasiroksi (Deferasiroxum).
Each dispersible tablet contains 136 mg lactose.
Igas dispergeeruvas tabletis on 136 mg laktoosi.
Each dispersible tablet contains 2 mg everolimus.
Iga dispergeeruv tablett sisaldab 2 mg everoliimust (Everolimusum).
Each dispersible tablet contains 2.94 mg lactose.
Iga dispergeeruv tablett sisaldab 2,94 mg laktoosi.
Each dispersible tablet contains 250 mg deferasirox.
Üks dispergeeruv tablett sisaldab 125 mg deferasiroksi (Deferasiroxum).
Each dispersible tablet contains 272 mg lactose.
Igas dispergeeruvas tabletis on 272 mg laktoosi.
Each dispersible tablet contains 3 mg everolimus.
Iga dispergeeruv tablett sisaldab 3 mg everoliimust (Everolimusum).
Each dispersible tablet contains 32 mg bosentan (as monohydrate).
Iga dispergeeruv tablett sisaldab 32 mg bosentaani (monohüdraadina).
Each dispersible tablet contains 32 mg of bosentan (as monohydrate).
Iga dispergeeruv tablett sisaldab 32 mg bosentaani (bosentaanmonohüdraadina).
Each dispersible tablet contains 4.90 mg lactose.
Iga dispergeeruv tablett sisaldab 4,90 mg laktoosi.
Each dispersible tablet contains 5 mg everolimus.
Iga dispergeeruv tablett sisaldab 5 mg everoliimust (Everolimusum).
Each dispersible tablet contains 500 mg deferasirox.
Üks dispergeeruv tablett sisaldab 125 mg deferasiroksi (Deferasiroxum).
Each dispersible tablet contains 544 mg lactose.
Igas dispergeeruvas tabletis on 544 mg laktoosi.
Each dispersible tablet of EXJADE 125 mg contains 125 mg deferasirox.
Üks EXJADE 125 mg dispergeeruv tablett sisaldab 125 mg deferasiroksi.
Each dispersible tablet of EXJADE 250 mg contains 250 mg deferasirox.
Üks EXJADE 250 mg dispergeeruv tablett sisaldab 250 mg deferasiroksi.
Each dispersible tablet of EXJADE 500 mg contains 500 mg deferasirox.
Üks EXJADE 500 mg dispergeeruv tablett sisaldab 500 mg deferasiroksi.
Each dose (0.007 ml) of undiluted vaccine contains
Üks annus (0,007 ml) lahjendamata vaktsiini sisaldab:
Each dose (0.2 ml) contains 10 micrograms (mcg) of lixisenatide (50 mcg per ml).
Üks annus (0,2 ml) sisaldab 10 mikrogrammi (µg) liksisenatiidi ( 50 µg/ml).
Each dose (0.2 ml) contains 10 micrograms (mcg) of lixisenatide (50 mcg per ml).
Üks annus (0,2 ml) sisaldab 10 mikrogrammi (µg) liksisenatiidi (50 µg/ml).
Each dose (0.2 ml) contains 10 micrograms lixisenatide.
Üks annus (0,2 ml) sisaldab 10 mikrogrammi liksisenatiidi.
Each dose (0.2 ml) contains 10 or 20 micrograms lixisenatide.
Üks annus (0,2 ml) sisaldab 10 või 20 mikrogrammi liksisenatiidi.
Each dose (0.2 ml) contains 20 micrograms (mcg) of lixisenatide (100 mcg per ml).
Üks annus (0,2 ml) sisaldab 20 mikrogrammi (µg) liksisenatiidi (100 µg /ml).
Each dose (0.2 ml) contains 20 micrograms (mcg) of lixisenatide (100 mcg per ml).
Üks annus (0,2 ml) sisaldab 20 mikrogrammi (µg) liksisenatiidi (100 µg/ml).
Each dose (0.2 ml) contains 20 micrograms lixisenatide.
Üks annus (0,2 ml) sisaldab 20 mikrogrammi liksisenatiidi.
Each dose (0.2 ml) of reconstituted suspension contains: Lyohpilisate:
Iga doos (0,2 ml) manustamiskõlblikuks muudetud suspensiooni sisaldab: Lüofilisaat:
Each dose (0.2 ml) of reconstituted vaccine contains:
Üks annus (0,2 ml) manustamiskõlblikuks muudetud vaktsiini sisaldab:
Each dose (2 ml) contains: gE deleted inactivated IBR virus, at least .............................................................................
Iga doos ( 2 ml) sisaldab: gE inaktiveeritud IBR viirus, vähemalt .................................................................................
Each dose (2 ml) contains: Live BVDV-1 and BVDV-2.
Üks doos (2 ml) sisaldab: elusviirusi BVDV-1 ja BVDV-2
Each dose (24 ml) contains 36 mg methyl parahydroxybenzoate (E218), 3.6 mg propyl parahydroxybenzoate (E216), 1.2 mg Sunset Yellow (E110) and has a sodium content of 36 mg.
Ühes annuses (24 ml) on 36 mg metüülparahüdroksübensoaati (E218), 3,6 mg propüülparahüdroksübensoaati (E216), 1,2 mg päikeseloojangukollast (E110); annuse naatriumisisaldus on 36 mg.
Each dose comes in a sealed plastic tray and has a white to off-white coloured powder in a glass container (vial) and an injection syringe filled with water.
Iga annuse komplekti kuulub suletud plastalus, klaasanum (viaal), mis sisaldab valget kuni kahvatukollast pulbrit, ja veega täidetud süstal süstimiseks.
Each dose consists of one vial of Cayston mixed with one ampoule of solvent.
Iga annus koosneb ühest Caystoni viaalist, mis on segatud ühe ampulli soolalahuse kui lahustiga.
Each dose contains 30 mg per 0.5 ml following reconstitution.
Üks 0,5 ml annus sisaldab pärast lahustamist 30 mg toimeainet.
Each dose contains 50 mg per 0.5 ml following reconstitution.
Üks 0,5 ml annus sisaldab pärast lahustamist 50 mg toimeainet.
Each dose contains 540 micrograms of metacresol.
Üks annus sisaldab 540 mikrogrammi metakresooli.
Each dose contains approximately 10 milligrams of lactose (as monohydrate).
Üks annus sisaldab ligikaudu 10 milligrammi laktoosi (monohüdraadina).
Each dose is given as two slow 250-mg injections lasting one to two minutes, with one injection being given into the muscle of each buttock.
Iga annus manustatakse kahe aeglase üks-kaks minutit kestva 250 mg süstina, mis kumbki tehakse eri tuhara lihasesse.
Each dose of 0.2 ml contains:
Üks 0,2 ml annus sisaldab:
Each dose of 1 ml contains Bluetongue Virus
Iga 1 ml doos sisaldab lammaste katarraalse palaviku (Bluetongue) viiruse:
Each dose of 1 ml contains:
1 ml annus sisaldab:
Each dose of 1 ml contains:
Iga 1 ml doos sisladab:
Each dose of 1 ml contains:
Üks 1 ml vaktsiini annus sisaldab:
Each dose of 1 ml contains:
Üks annus 1 ml sisaldab:
Each dose of 1 ml contains: Inactivated Leptospira strains:
Iga annus 1 ml sisaldab: Inaktiveeritud Leptospira tüved:
Each dose of 1 ml of vaccine (homogeneous milky white suspension) contains:
Iga 1 ml doos vaktsiini (homogeenne piimjasvalge suspensioon) sisaldab:
Each dose of 1 ml of vaccine (homogeneous milky white suspension) contains:
Iga 1 ml doos vaktsiini (homogeenne piimjasvalge suspensioon) sisaldab: Iga 1 ml doos sisaldab:
Each dose of 1 ml of vaccine (homogenous milky white suspension) contains:
Iga 1 ml annus vaktsiini (homogeenne piimjasvalge lahus) sisaldab järgmisi aineid:
Each dose of 1 ml of vaccine contains:
Iga doos 1 ml sisaldab:
Each dose of 1 ml vaccine contains:
Üks 1 ml vaktsiini annus sisaldab:
Each dose of 1 ml vaccine contains: Lyophilisate:
Iga 1 ml vaktsiini annus sisaldab: Lüofilisaat:
Each dose of 1ml contains Bluetongue Virus
Iga 1 ml doos sisaldab:
Each dose of 1ml contains:
1 ml annus sisaldab:
Each dose of 1ml contains:
Iga doos 1 ml sisaldab:
Each dose of 1ml of vaccine contains:
Iga 1 ml vaktsiiniannus sisaldab järgmisi aineid:
Each dose of 2 ml contains:
Iga 2 ml doos sisaldab:
Each dose of 2 ml contains:
Iga annus 2 ml sisaldab:
Each dose of 2 ml contains: gE deleted inactivated IBR virus, at least .............................................................................
Iga doos 2-ml sisaldab: gE kustutatud inaktiveeritud IBR viirust vähemalt ……………………………………..0.75 VN.U
Each dose of 2 ml contains: Live gE- tk- double-gene deleted bovine herpes virus type 1 (BoHV-1), strain CEDDEL: 106.3 – 107.3 CCID50.
Iga 2 ml annus sisaldab: kahe deleteeritud geeniga gE- tk- Veiste elus Herpesviirus-1 (BoHV-1), tüvi CEDDEL: 106.3 – 107.3 CCID50
Each dose of 2 ml of emulsion contains:
Iga 2 ml doos sisaldab:
Each dose of 2 ml of the vaccine contains:
Iga 2ml vaktsiini annus sisaldab:
Each dose of 2 ml of vaccine contains:
Iga 2ml doos vaktsiini sisaldab:
Each dose of 2 ml of vaccine contains:
Iga 2ml vaktsiini doos sisaldab:
Each dose of 2 ml: Live gE- tk- double-gene deleted bovine herpes virus type 1 (BoHV-1), strain CEDDEL: 106.3 – 107.3 CCID50.
Iga 2 ml annus sisaldab: kahe deleteeritud geeniga gE- tk- Veiste elus Herpesviirus-1 (BoHV-1), tüvi CEDDEL: 106.3 – 107.3 CCID50
Each dose of 80 microliters contains 20 micrograms of teriparatide*.
Iga 80 mikroliitrine annus sisaldab 20 mikrogrammi teriparatiidi.
Each dose of Byetta 10 micrograms solution for injection (injection) contains 10 micrograms exenatide in 40 microlitre.
Iga annus Byetta 10 mikrogrammi süstelahust sisaldab 10 mikrogrammi eksenatiidi 40 mikroliitris.
Each dose of Byetta 5 micrograms solution for injection (injection) contains 5 micrograms exenatide in 20 microlitre.
Iga annus Byetta 5 mikrogrammi süstelahust sisaldab 5 mikrogrammi eksenatiidi 20 mikroliitris.
Each dose of IONSYS delivers 40 micrograms of fentanyl.
IONSYS’i iga annusega manustatakse 40 mikrogrammi fentanüüli.
Each dose of Lyxumia 10 contains 10 micrograms of lixisenatide (50 micrograms per ml).
Üks annus Lyxumia 10 sisaldab 10 mikrogrammi liksisenatiidi (50 mikrogrammi ml-s).
Each dose of Lyxumia 20 contains 20 micrograms of lixisenatide (100 micrograms per ml).
Üks annus Lyxumia 20 sisaldab 20 mikrogrammi liksisenatiidi (100 mikrogrammi ml-s).
Each dose of orodispersible tablet contains 2.5 mg desloratadine.
Suus dispergeeruva tableti iga annus sisaldab 2,5 mg desloratadiini.
Each dose of orodispersible tablet contains 5 mg desloratadine.
Suus dispergeeruva tableti iga annus sisaldab 5 mg desloratadiini.
Each dose of Posaconazole SP should be administered with a meal, or with a nutritional supplement in patients who cannot tolerate food to enhance the oral absorption and to ensure adequate exposure.
Imendumise parandamiseks suukaudsel manustamisel ning adekvaatse toime tagamiseks tuleb iga Posaconazole SP’i annus manustada koos toiduga või toidulisandiga neil patsientidel, kes ei talu toitu.
Each dose of Posaconazole SP should be taken with food or a nutritional supplement if you are unable to tolerate food to enhance the oral absorption.
Suukaudsel manustamisel tuleb imendumise parandamiseks iga Posaconazole SP’i annus võtta koos toiduga või toidulisandiga neil patsientidel, kes ei talu toitu.
Each dose of Provenge is preceded by a standard leukepheresis procedure approximately 3 days prior to the scheduled infusion date.
Igale Provenge annusele eelneb ligikaudu 3 päeva enne planeeritud infundeerimispäeva standardne leukafereesi protseduur.
Each dose of Provenge requires a standard leukapheresis procedure approximately 3 days prior to the infusion.
Igale Provenge annusele peab eelnema ligikaudu 3 päeva enne planeeritud infundeerimispäeva standardne leukafereesi protseduur.
Each dose of reconstituted vaccine contains:
Iga viaal sisaldab annuse kohta:
Each dose of vaccine comes with one sachet package that contains white effervescent granules of sodium hydrogen carbonate.
Iga vaktsiiniannusega on kaasas üks kotike, mis sisaldab naatriumvesinikkarbonaadi kihisevaid graanuleid.
Each dose of vaccine is supplied with one sachet of effervescent granules.
Iga vaktsiiniannusega on kaasas kotike kihisevate graanulitega.
Each dose of vaccine suspension (3 ml) contains:
Üks vaktsiinisuspensiooni annus (3 ml) sisaldab:
Each dose should be administered as a subcutaneous injection in the thigh, abdomen, or upper arm.
Iga annus tuleb manustada nahaaluse süstina kas reide, kõhtu või õlavarde.
Each dose should be rounded up to the nearest 0.5 ml.
Iga annus tuleb ümardada lähima 0,5 ml-ni.
Each dose will last for 10 minutes.
Iga annuse manustamine kestab 10 minutit.
Each drop contains 1 mg vortioxetine (as (D,L)- lactate)
Üks tilk sisaldab 1 mg vortioxetinum ((D,L)-laktaadina).
Each drop contains 1 mg vortioxetine.
Üks tilk sisaldab 1 mg vortioksetiini.
Each drop of solution contains 1 mg vortioxetine (as (D,L)- lactate).
Lahuse üks tilk sisaldab 1 mg vortioksetiini ((D,L)-laktaadina).
Each Efavirenz Teva film-coated tablet contains 600 mg of the active substance efavirenz.
Üks Efavirenz Teva tablett sisaldab 600 mg toimeainet efavirensi.
Each Eucreas 50 mg/1000 mg film-coated tablet contains 50 mg vildagliptin and 1000 mg metformin hydrochloride (corresponding to 780 mg of metformin).
Iga Eucreas 50 mg/1000 mg õhukese polümeerikattega tablett sisaldab 50 mg vildagliptiini ja 1000 mg metformiinvesinikkloriidi (vastab 780 mg metformiinile).
Each Eucreas 50 mg/850 mg film-coated tablet contains 50 mg vildagliptin and 850 mg metformin hydrochloride (corresponding to 660 mg of metformin).
Iga Eucreas 50 mg/850 mg õhukese polümeerikattega tablett sisaldab 50 mg vildagliptiini ja 850 mg metformiinvesinikkloriidi (vastab 660 mg metformiinile).
Each Eviplera film-coated tablet contains 200 mg of emtricitabine, 25 mg of rilpivirine (as hydrochloride) and 245 mg of tenofovir disoproxil (as fumarate).
Eviplera õhukese polümeerikattega tablett sisaldab 200 mg emtritsitabiini, 25 mg rilpiviriini (vesinikkloriidina) ja 245 mg tenofoviirdisoproksiili (fumaraadina).
Each film coated tablet contains 12.5 mg of ombitasvir, 75 mg of paritaprevir and 50 mg of ritonavir.
Üks õhukese polümeerikattega tablett sisaldab 12,5 mg ombitasviiri, 75 mg paritapreviiri ja 50 mg ritonaviiri.
Each film- coated tablet contains 75 mg of clopidogrel (as hydrochloride).
Iga õhukese polümeerikattega tablett sisaldab 75 mg klopidogreeli (vesinikkloriidina).
Each film-coated tablet also contains lactose
Iga õhukese polümeerikattega tablett sisaldab ka laktoosi
Each film-coated tablet also contains lactose and lecithin (soya) (E322).
Iga õhukese polümeerikattega tablett sisaldab ka laktoosi ja letsitiini (soja) (E322).
Each film-coated tablet contains 0.0025 mg sunset yellow FCF aluminium lake (E110) and 0.6065 mg propylene glycol (E1520).
Üks õhukese polümeerikattega tablett sisaldab 0,0025 mg värvainet päikeseloojangukollane FCF alumiiniumlakk (E110) ja 0,6065 mg propüleenglükooli (E1520).
Each film-coated tablet contains 0.013 mg of sunset yellow FCF (E110)
Iga õhukese polümeerikattega tablett sisaldab 0,013 mg päikeseloojangukollast FCF (E110)
Each film-coated tablet contains 0.08 mg sunset yellow FCF aluminium lake (E110).
Üks õhukese polümeerikattega tablett sisaldab 0,08 mg värvainet päikeseloojangukollane FCF alumiiniumlakk (E110).
Each film-coated tablet contains 0.19 mg lecithin (soya) (E322) For the full list of excipients, see section 6.1.
Üks õhukese polümeerikattega tablett sisaldab 0,19 mg letsitiini (soja) (E322) Abiainete täielik loetelu vt lõik 6.1.
Each film-coated tablet contains 0.19 mg of sunset yellow FCF (E110).
Üks tablett sisaldab 0,19 mg värvainet päikeseloojangukollane FCF (E110).
Each film-coated tablet contains 0.47 mg lactose monohydrate.
Üks õhukese polümeerikattega tablett sisaldab 0,47 mg laktoosmonohüdraati.